Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Ferrari

Showing results (441-450 of 547) with videos related to

Pageof 55
Sort By:
JAMA|May 5, 2005
Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trialMarco Valgimigli, Gianfranco Percoco, Patrizia Malagutti, et al.
Journal of Clinical Medicine|July 24, 2021
The Combination of Chest Computed Tomography and Standard Electrocardiogram Provides Prognostic Information and Pathophysiological Insights in COVID-19 PneumoniaMatteo Bertini, Emanuele D'Aniello, Alberto Cereda, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 8, 2012
Does the site of bleeding matter? A stratified analysis on location of TIMI-graded bleedings and their impact on 12-month outcome in patients with ST-segment elevation myocardial infarctionPascal Vranckx, Gianluca Campo, Maurizio Anselmi, et al.
Molecular Medicine (Cambridge, Mass.)|May 23, 2007
Factor XIIIA-V34L and factor XIIIB-H95R gene variants: effects on survival in myocardial infarction patientsDonato Gemmati, Federica Federici, Gianluca Campo, et al.
European Journal of Preventive Cardiology|January 13, 2022
Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicitiesKoon-Hou Mak, Emmanuelle Vidal-Petiot, Robin Young, et al.
Circulation|June 17, 2009
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel studyMarco Valgimigli, Gianluca Campo, Nicoletta de Cesare, et al.
Cellular and Molecular Life Sciences : CMLS|February 22, 2024
A progesterone derivative linked to a stable phospholipid activates breast cancer cell response without leaving the cell membraneJofre Font-Mateu, Pol Sanllehí, Jesús Sot, et al.
International Journal of Molecular Sciences|September 23, 2022
Circulating Biomarkers of Endothelial Dysfunction and Inflammation in Predicting Clinical Outcomes in Diabetic Patients with Critical Limb IschemiaFrancesco Vieceli Dalla Sega, Paolo Cimaglia, Marco Manfrini, et al.
Aging Clinical and Experimental Research|November 1, 2016
The frailty in elderly patients receiving cardiac interventional procedures (FRASER) program: rational and design of a multicenter prospective studyGianluca Campo, Rita Pavasini, Elisa Maietti, et al.
Cardiovascular Diabetology|June 20, 2014
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)Bernard Zinman, Silvio E Inzucchi, John M Lachin, et al.
Pageof 55

Showing results (441-450 of 547) with videos related to

Sort By:
Pageof 55
JAMA|May 5, 2005
Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trialMarco Valgimigli, Gianfranco Percoco, Patrizia Malagutti, et al.
Journal of Clinical Medicine|July 24, 2021
The Combination of Chest Computed Tomography and Standard Electrocardiogram Provides Prognostic Information and Pathophysiological Insights in COVID-19 PneumoniaMatteo Bertini, Emanuele D'Aniello, Alberto Cereda, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|February 8, 2012
Does the site of bleeding matter? A stratified analysis on location of TIMI-graded bleedings and their impact on 12-month outcome in patients with ST-segment elevation myocardial infarctionPascal Vranckx, Gianluca Campo, Maurizio Anselmi, et al.
Molecular Medicine (Cambridge, Mass.)|May 23, 2007
Factor XIIIA-V34L and factor XIIIB-H95R gene variants: effects on survival in myocardial infarction patientsDonato Gemmati, Federica Federici, Gianluca Campo, et al.
European Journal of Preventive Cardiology|January 13, 2022
Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicitiesKoon-Hou Mak, Emmanuelle Vidal-Petiot, Robin Young, et al.
Circulation|June 17, 2009
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel studyMarco Valgimigli, Gianluca Campo, Nicoletta de Cesare, et al.
Cellular and Molecular Life Sciences : CMLS|February 22, 2024
A progesterone derivative linked to a stable phospholipid activates breast cancer cell response without leaving the cell membraneJofre Font-Mateu, Pol Sanllehí, Jesús Sot, et al.
International Journal of Molecular Sciences|September 23, 2022
Circulating Biomarkers of Endothelial Dysfunction and Inflammation in Predicting Clinical Outcomes in Diabetic Patients with Critical Limb IschemiaFrancesco Vieceli Dalla Sega, Paolo Cimaglia, Marco Manfrini, et al.
Aging Clinical and Experimental Research|November 1, 2016
The frailty in elderly patients receiving cardiac interventional procedures (FRASER) program: rational and design of a multicenter prospective studyGianluca Campo, Rita Pavasini, Elisa Maietti, et al.
Cardiovascular Diabetology|June 20, 2014
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)Bernard Zinman, Silvio E Inzucchi, John M Lachin, et al.
Pageof 55